TNYA — Tenaya Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $338.41m
- $233.77m
- 35
- 18
- 62
- 32
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 27.7 | 38.9 | 72.8 | 126 | 131 |
Operating Profit | -27.7 | -38.9 | -72.8 | -126 | -131 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -26.2 | -38.4 | -72.7 | -124 | -124 |
Provision for Income Taxes | |||||
Net Income After Taxes | -26.2 | -38.4 | -72.7 | -124 | -124 |
Net Income Before Extraordinary Items | |||||
Net Income | -26.2 | -38.4 | -72.7 | -124 | -124 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -26.2 | -38.4 | -72.7 | -124 | -124 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.667 | -0.976 | -4.1 | -2.76 | -1.68 |
Dividends per Share |